Literature DB >> 16832586

Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Silvia Regina Correa-Silva1, Sérgio Oliva Nascif, Ana-Maria Judith Lengyel.   

Abstract

GH responsiveness to GH secretagogues (GHS) is blunted in Cushing's disease (CD), while ACTH/cortisol responses are enhanced, by mechanisms still unclear. Ghrelin, the endogenous ligand for GHS-receptors (GHS-R), increases GH, ACTH, cortisol and glucose levels in humans. This study evaluated the GH, ACTH, cortisol and glucose-releasing effects of ghrelin in CD in comparison with GHRP-6. GHRH-induced GH release was also studied. Ten patients with CD (BMI 26.9+/-1.0 kg/m(2)) and ten controls (BMI 24.4+/-1.1 kg/m(2)) received ghrelin (1 microg/kg), GHRP-6 (1 microg/kg) and GHRH (100 microg) separately. GH, ACTH, cortisol and glucose levels were measured. In CD ghrelin-induced GH (microg/L; mean +/- SE) release (peak: 7.2+/-3.0) was higher than seen with GHRP-6 (2.7+/-1.0) and GHRH (0.7+/-0.2), but lower than in controls (ghrelin: 58.3+/-12.1; GHRP-6: 22.9+/-4.8; GHRH: 11.3+/-3.7). In controls ACTH (pg/mL) release after ghrelin (79.2+/-26.8) was higher than after GHRP-6 (23.6+/-5.7). In CD these responses (ghrelin: 192+/-43; GHRP-6: 185+/-56) were similar, and enhanced compared to controls. The same was observed with cortisol. Glucose levels failed to increase after ghrelin in CD, differently than in controls. Our data suggests that hypothalamic and pituitary pathways of GH release activated by ghrelin, GHRP-6 and GHRH are deranged in chronic hypercortisolism. The increased ACTH/cortisol responses to ghrelin and GHRP-6 in CD could be mediated by overexpression of GHS-R in ACTH-secreting adenomas. Hypercortisolism apparently impairs the ability of ghrelin to increase glucose levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16832586     DOI: 10.1007/s11102-006-9149-8

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  48 in total

1.  GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Authors:  J H A Oliveira; J G H Vieira; J Abucham; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

2.  Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.

Authors:  E Ghigo; E Arvat; J Ramunni; A Colao; L Gianotti; R Deghenghi; G Lombardi; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

3.  Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin.

Authors:  G S Tannenbaum; C Y Bowers
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

4.  The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors.

Authors:  M Korbonits; S A Bustin; M Kojima; S Jordan; E F Adams; D G Lowe; K Kangawa; A B Grossman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

5.  The negative association between total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease.

Authors:  Roberta Giordano; Andrea Picu; Uberto Pagotto; Rosaria De Iasio; Lorenza Bonelli; Flavia Prodam; Fabio Broglio; Lisa Marafetti; Renato Pasquali; Mauro Maccario; Ezio Ghigo; Emanuela Arvat
Journal:  Eur J Endocrinol       Date:  2005-10       Impact factor: 6.664

6.  Adrenocorticotropin/cortisol and arginine-vasopressin secretory patterns in response to ghrelin in normal men.

Authors:  Vittorio Coiro; Gloria Saccani-Jotti; Roberta Minelli; Andrea Melani; Bruna Milli; Guido Manfredi; Riccardo Volpi; Paolo Chiodera
Journal:  Neuroendocrinology       Date:  2005       Impact factor: 4.914

7.  Ghrelin strongly stimulates growth hormone release in humans.

Authors:  K Takaya; H Ariyasu; N Kanamoto; H Iwakura; A Yoshimoto; M Harada; K Mori; Y Komatsu; T Usui; A Shimatsu; Y Ogawa; K Hosoda; T Akamizu; M Kojima; K Kangawa; K Nakao
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

8.  The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.

Authors:  M Korbonits; G Kaltsas; L A Perry; P Putignano; A B Grossman; G M Besser; P J Trainer
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

9.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

10.  Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin.

Authors:  A M Mozid; G Tringali; M L Forsling; M S Hendricks; S Ajodha; R Edwards; P Navarra; A B Grossman; M Korbonits
Journal:  Horm Metab Res       Date:  2003-08       Impact factor: 2.936

View more
  6 in total

1.  ACTH and cortisol responses to ghrelin and desmopressin in patients with Cushing's disease and adrenal enlargement.

Authors:  D Miljic; M Joksimovic; M Doknic; M Ivovic; M Djurovic; S Pekic; M Tancic; I Soldatovic; M Stojanovic; Dj Nale; Dj Macut; S Damjanovic; V Popovic
Journal:  J Endocrinol Invest       Date:  2010-02-05       Impact factor: 4.256

Review 2.  Clinical review: The human experience with ghrelin administration.

Authors:  Margaret C Garin; Carrie M Burns; Shailja Kaul; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

3.  Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis.

Authors:  Sergio Oliva Nascif; Patrícia Molica; Silvia Regina Correa-Silva; Marcos Roberto Silva; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2009-04-26       Impact factor: 4.107

4.  Acute ghrelin response to intravenous dexamethasone administration in idiopathic short stature or isolated idiopathic growth hormone-deficient children.

Authors:  G Radetti; F Prodam; S Lauriola; G Di Dio; G D'Addato; G Corneli; S Bellone; G Bona
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

Review 5.  Structure and physiological actions of ghrelin.

Authors:  Christine Delporte
Journal:  Scientifica (Cairo)       Date:  2013-11-28

6.  Ghrelin Represses Thymic Stromal Lymphopoietin Gene Expression through Activation of Glucocorticoid Receptor and Protein Kinase C Delta in Inflamed Skin Keratinocytes.

Authors:  Hayan Jeong; Hyo-Jin Chong; Jangho So; Yejin Jo; Tae-Young Yune; Bong-Gun Ju
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.